VIVEbiotech announces significant growth in 2023
San Sebastián, Spain, December 14, 2023 - VIVEbiotech, S.L., a GMP contract development and manufacturing organization (CDMO) full...
FDA Investigating Serious Risk of T-cell Malignancy
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T...